Acromegaly Safety Monitoring Program

An Acromegaly Safety Monitoring Program for Treating Patients with Pasireotide LAR who are in need of Medical Therapy (ACCESS Study)This study will provide acromegalic patients, for whom medical therapy is appropriate, access to paseriotide LAR while regulatory approval is sought. Potential patients must: -be age 18 or older -have confirmed diagnosis of active acromegaly (caused by GH producing pituitary tumor) -not be controlled by pituitary surgery or not be eligible or refuse surgery

Primary Sponsor:
Novartis Pharmaceuticals

Prinicipal Investigator:
Zachary Litvack

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):